CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 8, 2020--
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the H. C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020.
Event: H. C. Wainwright 22nd Annual Global Investment Conference
Date: September 15, 2020
Time: 10:30 - 10:50 AM ET
A live webcast of the Company’s presentation will be accessible from the Investors & Media section of the Sesen Bio website, www.sesenbio.com. An archived replay of the webcast will be available on the Company's website for 90 days after the conference.
About Sesen Bio
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company’s lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2019, the Company initiated the BLA submission for Vicineum to the FDA under Rolling Review. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China, for which the Company has partnered with Qilu Pharmaceutical for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC. For more information, please visit the company’s website at www.sesenbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005078/en/
Erin Clark, Vice President, Corporate Strategy & Investor Relations
Source: Sesen Bio, Inc.